Patents by Inventor Ottheinz Krebs

Ottheinz Krebs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTIMIZED PARVOVIRUS H-1 PRODUCTION
    Publication number: 20220169992
    Abstract: The present invention provides a robust single clone Master Cell Bank (MCB) for an optimized production of H-1 parvovirus (H-1 PV) which is suitable to increase infectious parvovirus production compared to standard producer NB-324K mixed cells.
    Type: Application
    Filed: December 6, 2021
    Publication date: June 2, 2022
    Inventors: Barbara LEUCHS, Veronika FREHTMAN, Marcus MÜLLER, Jean ROMMELAERE, Michael DAHM, Ottheinz KREBS
  • Parvovirus formulation for treating tumors
    Patent number: 11324788
    Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: May 10, 2022
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Barbara Leuchs, Karsten Geletneky, Jean Rommelaere, Christiane Dinsart, Michael Dahm, Ottheinz Krebs
  • PARVOVIRUS FORMULATION FOR TREATING TUMORS
    Publication number: 20200215134
    Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.
    Type: Application
    Filed: March 20, 2020
    Publication date: July 9, 2020
    Inventors: Barbara Leuchs, Karsten Geletneky, Jean Rommelaere, Christiane DINSART, Michael Dahm, Ottheinz KREBS
  • Parvovirus formulation for treating tumors
    Patent number: 10624935
    Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2×2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium. A preferred use is the therapy of a brain tumour by intratumoral injection.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: April 21, 2020
    Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
    Inventors: Barbara Leuchs, Karsten Geletneky, Jean Rommelaere, Christiane Dinsart, Michael Dahm, Ottheinz Krebs
  • PARVOVIRUS FORMULATION FOR TREATING TUMORS
    Publication number: 20180110813
    Abstract: Described is a parvovirus formulation which comprises (a) at least 1×109 pfu/ml of parvovirus H1 (H-1PV) or a related rodent parvovirus such as LuIII, Mouse minute virus (MMV), Mouse parvovirus (MPV), Rat minute virus (RMV), Rat parvovirus or Rat virus (RV) and (b) a pharmaceutically acceptable carrier containing 40-50% Iodixanol (w/v), 0.7-0.9 mmol CaCl2 x 2 H2O, 50-60 mmol NaCl, 0.9-1.2 mmol KCl, 0.7-0.95 mg/ml Tromethamine and 0.05-0.15 mg/ml Edetate calcium disodium.. A preferred use is the therapy of a brain tumour by intratumoral injection.
    Type: Application
    Filed: December 4, 2017
    Publication date: April 26, 2018
    Inventors: Barbara Leuchs, Karsten Geletneky, Jean Rommelaere, Christiane Dinsart, Michael Dahm, Ottheinz Krebs